Literature DB >> 1289359

A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies.

M J Leyland1, K F Bayston, J Cohen, R Warren, A C Newland, A J Bint, C Cefai, D G White, S A Murray, D Bareford.   

Abstract

Three-hundred and twelve episodes of fever in 234 neutropenic patients with haematological malignancies were treated empirically with either imipenem or a combination of piperacillin and gentamicin. There were no significant differences in the percentages of patients responding to therapy at either 72 h (59% and 56% of assessable episodes in the imipenem and combination groups respectively) or at the end of treatment (55% and 53% of assessable episodes in the imipenem and combination groups respectively). Patients in the piperacillin plus gentamicin group experienced significantly more renal tubular damage whereas those who received imipenem suffered more nausea or vomiting. We conclude that imipenem monotherapy represents an acceptable alternative to piperacillin plus gentamicin as empirical therapy of the febrile neutropenic patient.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1289359     DOI: 10.1093/jac/30.6.843

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

Review 1.  Management of febrile neutropenia in low risk cancer patients.

Authors:  B A Oppenheim; H Anderson
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

2.  Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.

Authors:  A Cometta; T Calandra; H Gaya; S H Zinner; R de Bock; A Del Favero; G Bucaneve; F Crokaert; W V Kern; J Klastersky; I Langenaeken; A Micozzi; A Padmos; M Paesmans; C Viscoli; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.

Authors:  G G Zhanel; A E Simor; L Vercaigne; L Mandell
Journal:  Can J Infect Dis       Date:  1998-07

Review 4.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial.

Authors:  L Gómez; C Estrada; I Gómez; M Márquez; C Estany; J M Martí; R Bastús; L Cirera; S Quintana; J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-02-27       Impact factor: 3.267

6.  Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in Germany.

Authors:  E S Dietrich; E Patz; U Frank; F D Daschner
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

7.  Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.

Authors:  A Jimeno; A Arcediano; S Bazares; M L Amador; L González-Cortijo; E Ciruelos; L Robles; D Castellano; L Paz-Ares; C Lumbreras; J Hornedo; H Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2006-12       Impact factor: 3.405

8.  The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients.

Authors:  Michael J Satlin; Rosemary Soave; Alexandra C Racanelli; Tsiporah B Shore; Koen van Besien; Stephen G Jenkins; Thomas J Walsh
Journal:  Leuk Lymphoma       Date:  2014-03-24

9.  Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children.

Authors:  N Le Guyader; A Auvrignon; H Vu-Thien; E Portier; M D Tabone; G Leverger
Journal:  Support Care Cancer       Date:  2004-10       Impact factor: 3.603

Review 10.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.